What is Avazzia?
Avazzia is at the forefront of developing and distributing microcurrent devices designed to offer prescription-level pain relief for both acute and chronic conditions. Leveraging clinically researched technology, their product portfolio serves a broad clientele, including healthcare providers, veterans, athletes, and individuals managing pain from various ailments. The company offers a range of devices, from over-the-counter options to prescription-required units, all underpinned by a commitment to evidence-based research aimed at improving patient outcomes. Avazzia's dedication extends to supporting veterans through specialized initiatives, underscoring their mission to serve those who have served.
How much funding has Avazzia raised?
Avazzia has raised a total of $424K across 2 funding rounds:
Debt
$150K
Debt
$274K
Debt (2020): $150K with participation from PPP
Debt (2021): $274K led by PPP
What's next for Avazzia?
With the recent strategic investment and substantial overall capital, Avazzia is poised for accelerated growth and market penetration. This significant backing, indicative of a late-stage funding round, suggests a focus on scaling operations, enhancing product development, and potentially expanding its distribution channels. The company's emphasis on clinically validated microcurrent technology for pain management aligns with growing market demand for non-invasive therapeutic solutions. Future strategic moves are likely to involve further innovation in device efficacy and broader market outreach, solidifying Avazzia's position as a key player in the pain relief technology landscape.
See full Avazzia company page
